Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAge Labs (BIOA) Accumulated Expenses (2024 - 2025)

BioAge Labs (BIOA) has disclosed Accumulated Expenses for 2 consecutive years, with $4.4 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 62.96% to $4.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.4 million through Dec 2025, down 62.96% year-over-year, with the annual reading at $4.4 million for FY2025, 62.96% down from the prior year.
  • Accumulated Expenses hit $4.4 million in Q4 2025 for BioAge Labs, down from $7.3 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $11.8 million in Q4 2024 to a low of $2.3 million in Q2 2025.